IL129299A0 - Monoclonal antibodies antigens and diagnosis of malignant diseases - Google Patents

Monoclonal antibodies antigens and diagnosis of malignant diseases

Info

Publication number
IL129299A0
IL129299A0 IL12929999A IL12929999A IL129299A0 IL 129299 A0 IL129299 A0 IL 129299A0 IL 12929999 A IL12929999 A IL 12929999A IL 12929999 A IL12929999 A IL 12929999A IL 129299 A0 IL129299 A0 IL 129299A0
Authority
IL
Israel
Prior art keywords
peptides
mabs
malignant diseases
monoclonal antibodies
diagnosis
Prior art date
Application number
IL12929999A
Other languages
English (en)
Original Assignee
Mor Research Applic Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mor Research Applic Ltd filed Critical Mor Research Applic Ltd
Priority to IL12929999A priority Critical patent/IL129299A0/xx
Priority to DE69922261T priority patent/DE69922261T2/de
Priority to CNB998165425A priority patent/CN1267452C/zh
Priority to HU0200537A priority patent/HUP0200537A2/hu
Priority to AT99973801T priority patent/ATE283289T1/de
Priority to IL14553599A priority patent/IL145535A0/xx
Priority to AU59965/99A priority patent/AU776464C/en
Priority to PCT/IL1999/000518 priority patent/WO2000058363A1/en
Priority to EP99973801A priority patent/EP1165616B1/en
Priority to NZ513498A priority patent/NZ513498A/xx
Priority to JP2000608655A priority patent/JP2003500015A/ja
Priority to CA2367901A priority patent/CA2367901C/en
Priority to RU2001126052/13A priority patent/RU2235131C2/ru
Priority to KR1020017012384A priority patent/KR20020008140A/ko
Priority to BR9917218-6A priority patent/BR9917218A/pt
Publication of IL129299A0 publication Critical patent/IL129299A0/xx
Priority to ZA200106809A priority patent/ZA200106809B/en
Priority to IL145535A priority patent/IL145535A/en
Priority to US09/967,719 priority patent/US20030026800A1/en
Priority to US11/315,067 priority patent/US7695715B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57419—Specifically defined cancers of colon
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57434—Specifically defined cancers of prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IL12929999A 1999-03-31 1999-03-31 Monoclonal antibodies antigens and diagnosis of malignant diseases IL129299A0 (en)

Priority Applications (19)

Application Number Priority Date Filing Date Title
IL12929999A IL129299A0 (en) 1999-03-31 1999-03-31 Monoclonal antibodies antigens and diagnosis of malignant diseases
NZ513498A NZ513498A (en) 1999-03-31 1999-09-30 Monoclonal antibodies, antigens and diagnosis and therapy of malignant diseases
JP2000608655A JP2003500015A (ja) 1999-03-31 1999-09-30 モノクローナル抗体、抗原ならびに悪性疾患の診断および治療
HU0200537A HUP0200537A2 (en) 1999-03-31 1999-09-30 Monoclonal antibodies, antigens and diagnosis and therapy of malignant diseases
AT99973801T ATE283289T1 (de) 1999-03-31 1999-09-30 Monoklonale antikörper, antigene sowie diagnose und therapie von bösartigen krankheiten
IL14553599A IL145535A0 (en) 1999-03-31 1999-09-30 Monoclonal antibodies, antigens and diagnosis and therapy of malignant diseases
AU59965/99A AU776464C (en) 1999-03-31 1999-09-30 Monoclonal antibodies, antigens and diagnosis and therapy of malignant diseases
PCT/IL1999/000518 WO2000058363A1 (en) 1999-03-31 1999-09-30 Monoclonal antibodies, antigens and diagnosis and therapy of malignant diseases
EP99973801A EP1165616B1 (en) 1999-03-31 1999-09-30 Monoclonal antibodies, antigens and diagnosis and therapy of malignant diseases
DE69922261T DE69922261T2 (de) 1999-03-31 1999-09-30 Monoklonale antikörper, antigene sowie diagnose und therapie von bösartigen krankheiten
CNB998165425A CN1267452C (zh) 1999-03-31 1999-09-30 单克隆抗体、抗原和恶性疾病的诊断和治疗
CA2367901A CA2367901C (en) 1999-03-31 1999-09-30 Monoclonal antibodies, antigens and diagnosis and therapy of malignant diseases
RU2001126052/13A RU2235131C2 (ru) 1999-03-31 1999-09-30 Моноклональное антитело, нуклеиновая кислота и вектор, кодирующие антитело, и использование антитела для диагностики и лечения злокачественных заболеваний
KR1020017012384A KR20020008140A (ko) 1999-03-31 1999-09-30 단일클론 항체, 항원 및 악성 질환의 진단 및 치료
BR9917218-6A BR9917218A (pt) 1999-03-31 1999-09-30 Anticorpos monoclonais, antìgenos, e diagnósticoe terapia de doenças malignas
ZA200106809A ZA200106809B (en) 1999-03-31 2001-08-17 Monoclonal antibodies, antigens and diagnosis and therapy of malignant diseases.
IL145535A IL145535A (en) 1999-03-31 2001-09-21 Monoclonal antibodies, antigens and diagnosis and treatment of malignant diseases
US09/967,719 US20030026800A1 (en) 1999-03-31 2001-09-28 Monoclonal antibodies, antigens and diagnosis and therapy of malignant diseases
US11/315,067 US7695715B2 (en) 1999-03-31 2005-12-23 Monoclonal antibodies, antigens and diagnosis and therapy of malignant diseases

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IL12929999A IL129299A0 (en) 1999-03-31 1999-03-31 Monoclonal antibodies antigens and diagnosis of malignant diseases

Publications (1)

Publication Number Publication Date
IL129299A0 true IL129299A0 (en) 2000-02-17

Family

ID=11072675

Family Applications (3)

Application Number Title Priority Date Filing Date
IL12929999A IL129299A0 (en) 1999-03-31 1999-03-31 Monoclonal antibodies antigens and diagnosis of malignant diseases
IL14553599A IL145535A0 (en) 1999-03-31 1999-09-30 Monoclonal antibodies, antigens and diagnosis and therapy of malignant diseases
IL145535A IL145535A (en) 1999-03-31 2001-09-21 Monoclonal antibodies, antigens and diagnosis and treatment of malignant diseases

Family Applications After (2)

Application Number Title Priority Date Filing Date
IL14553599A IL145535A0 (en) 1999-03-31 1999-09-30 Monoclonal antibodies, antigens and diagnosis and therapy of malignant diseases
IL145535A IL145535A (en) 1999-03-31 2001-09-21 Monoclonal antibodies, antigens and diagnosis and treatment of malignant diseases

Country Status (16)

Country Link
US (2) US20030026800A1 (xx)
EP (1) EP1165616B1 (xx)
JP (1) JP2003500015A (xx)
KR (1) KR20020008140A (xx)
CN (1) CN1267452C (xx)
AT (1) ATE283289T1 (xx)
AU (1) AU776464C (xx)
BR (1) BR9917218A (xx)
CA (1) CA2367901C (xx)
DE (1) DE69922261T2 (xx)
HU (1) HUP0200537A2 (xx)
IL (3) IL129299A0 (xx)
NZ (1) NZ513498A (xx)
RU (1) RU2235131C2 (xx)
WO (1) WO2000058363A1 (xx)
ZA (1) ZA200106809B (xx)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1225233A3 (en) * 2001-01-23 2003-01-08 Amsterdam Support Diagnostics B.V. Means and methods for treatment evaluation
IL145926A0 (en) 2001-10-15 2002-07-25 Mor Research Applic Ltd Peptide epitopes of mimotopes useful in immunomodulation
IL149820A0 (en) 2002-05-23 2002-11-10 Curetech Ltd Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency
WO2006021955A2 (en) * 2004-08-23 2006-03-02 Mor Research Applications Ltd. Use of bat monoclonal antibody for immunotherapy
CA2652703C (en) * 2006-06-07 2018-08-28 Bioalliance C.V. Antibodies recognizing a carbohydrate containing epitope on cd-43 and cea expressed on cancer cells and methods using same
NZ600758A (en) 2007-06-18 2013-09-27 Merck Sharp & Dohme Antibodies to human programmed death receptor pd-1
CN104548091A (zh) * 2008-02-11 2015-04-29 治疗科技公司 用于肿瘤治疗的单克隆抗体
DK2734205T3 (en) 2011-07-21 2018-06-14 Tolero Pharmaceuticals Inc Heterocyclic Protein Kinase Inhibitors
CA2840018C (en) 2011-07-24 2019-07-16 Curetech Ltd. Variants of humanized immunomodulatory monoclonal antibodies
EP2786151B1 (en) * 2011-11-29 2019-07-03 F.Hoffmann-La Roche Ag Methods for prostate cancer analysis
EP3049442A4 (en) 2013-09-26 2017-06-28 Costim Pharmaceuticals Inc. Methods for treating hematologic cancers
US9580504B1 (en) 2013-11-07 2017-02-28 Curetech Ltd. Pidilizumab monoclonal antibody therapy following stem cell transplantation
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
CA2960824A1 (en) 2014-09-13 2016-03-17 Novartis Ag Combination therapies of alk inhibitors
PE20181322A1 (es) 2015-09-01 2018-08-14 Agenus Inc Anticuerpo anti-pd1 y sus metodos de uso
KR20180107151A (ko) 2016-02-17 2018-10-01 노파르티스 아게 Tgf베타 2 항체
EP3468581A1 (en) 2016-06-13 2019-04-17 Torque Therapeutics, Inc. Methods and compositions for promoting immune cell function
WO2018094275A1 (en) 2016-11-18 2018-05-24 Tolero Pharmaceuticals, Inc. Alvocidib prodrugs and their use as protein kinase inhibitors
BR112019011582A2 (pt) 2016-12-07 2019-10-22 Agenus Inc. anticorpos e métodos de utilização dos mesmos
WO2018134784A1 (en) 2017-01-20 2018-07-26 Novartis Ag Combination therapy for the treatment of cancer
DK3579874T3 (da) 2017-02-10 2021-10-11 Novartis Ag 1-(4-amino-5-brom-6-(1h-pyrazol-1-yl)pyrimidin-2-yl)-1h-pyrazol-4-ol og anvendelse deraf til behandling af cancer
AR111760A1 (es) 2017-05-19 2019-08-14 Novartis Ag Compuestos y composiciones para el tratamiento de tumores sólidos mediante administración intratumoral
JOP20190279A1 (ar) 2017-05-31 2019-11-28 Novartis Ag الصور البلورية من 5-برومو -2، 6-داي (1h-بيرازول -1-يل) بيريميدين -4- أمين وأملاح جديدة
WO2018229715A1 (en) 2017-06-16 2018-12-20 Novartis Ag Compositions comprising anti-cd32b antibodies and methods of use thereof
WO2018237173A1 (en) 2017-06-22 2018-12-27 Novartis Ag ANTIBODY MOLECULES DIRECTED AGAINST CD73 AND CORRESPONDING USES
MA49457A (fr) 2017-06-22 2020-04-29 Novartis Ag Molécules d'anticorps se liant à cd73 et leurs utilisations
WO2019006007A1 (en) 2017-06-27 2019-01-03 Novartis Ag POSOLOGICAL REGIMES FOR ANTI-TIM3 ANTIBODIES AND USES THEREOF
AU2018302283A1 (en) 2017-07-20 2020-02-06 Novartis Ag Dosage regimens of anti-LAG-3 antibodies and uses thereof
WO2019055579A1 (en) 2017-09-12 2019-03-21 Tolero Pharmaceuticals, Inc. TREATMENT REGIME FOR CANCERS THAT ARE INSENSITIVE TO BCL-2 INHIBITORS USING THE MCL-1 ALVOCIDIB INHIBITOR
US20210040205A1 (en) 2017-10-25 2021-02-11 Novartis Ag Antibodies targeting cd32b and methods of use thereof
KR20200089286A (ko) 2017-11-16 2020-07-24 노파르티스 아게 조합 요법
RU2020121458A (ru) 2017-11-30 2021-12-30 Новартис Аг Химерный антигенный рецептор, нацеливающийся на bcma, и его пути применения
CN112218651A (zh) 2018-01-08 2021-01-12 诺华公司 用于与嵌合抗原受体疗法组合的免疫增强rna
WO2019152660A1 (en) 2018-01-31 2019-08-08 Novartis Ag Combination therapy using a chimeric antigen receptor
EP3752203A1 (en) 2018-02-13 2020-12-23 Novartis AG Chimeric antigen receptor therapy in combination with il-15r and il15
US20210147547A1 (en) 2018-04-13 2021-05-20 Novartis Ag Dosage Regimens For Anti-Pd-L1 Antibodies And Uses Thereof
AR126019A1 (es) 2018-05-30 2023-09-06 Novartis Ag Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
WO2019232244A2 (en) 2018-05-31 2019-12-05 Novartis Ag Antibody molecules to cd73 and uses thereof
CN112384531B (zh) 2018-06-01 2024-05-14 诺华股份有限公司 针对bcma的结合分子及其用途
WO2020021465A1 (en) 2018-07-25 2020-01-30 Advanced Accelerator Applications (Italy) S.R.L. Method of treatment of neuroendocrine tumors
WO2020044252A1 (en) 2018-08-31 2020-03-05 Novartis Ag Dosage regimes for anti-m-csf antibodies and uses thereof
WO2020049534A1 (en) 2018-09-07 2020-03-12 Novartis Ag Sting agonist and combination therapy thereof for the treatment of cancer
US20210348238A1 (en) 2018-10-16 2021-11-11 Novartis Ag Tumor mutation burden alone or in combination with immune markers as biomarkers for predicting response to targeted therapy
EP3890749A4 (en) 2018-12-04 2022-08-03 Sumitomo Dainippon Pharma Oncology, Inc. CDK9 INHIBITORS AND POLYMORPHS THEREOF FOR USE AS CANCER TREATMENT AGENT
WO2020167990A1 (en) 2019-02-12 2020-08-20 Tolero Pharmaceuticals, Inc. Formulations comprising heterocyclic protein kinase inhibitors
JP2022519385A (ja) 2019-02-12 2022-03-23 ノバルティス アーゲー Ｔｎｏ１５５及びｐｄ－１阻害剤を含む医薬組合せ
WO2020191326A1 (en) 2019-03-20 2020-09-24 Sumitomo Dainippon Pharma Oncology, Inc. Treatment of acute myeloid leukemia (aml) with venetoclax failure
CA3133460A1 (en) 2019-03-22 2020-10-01 Sumitomo Dainippon Pharma Oncology, Inc. Compositions comprising pkm2 modulators and methods of treatment using the same
JP2022539208A (ja) 2019-07-03 2022-09-07 スミトモ ファーマ オンコロジー， インコーポレイテッド チロシンキナーゼ非受容体１（ｔｎｋ１）阻害剤およびその使用
TW202124446A (zh) 2019-09-18 2021-07-01 瑞士商諾華公司 與ｅｎｔｐｄ２抗體之組合療法
JP2022548881A (ja) 2019-09-18 2022-11-22 ノバルティス アーゲー Ｅｎｔｐｄ２抗体、組合せ療法並びに抗体及び組合せ療法を使用する方法
IL292347A (en) 2019-10-21 2022-06-01 Novartis Ag Combination treatments with ventoclax and tim-3 inhibitors
AU2020370832A1 (en) 2019-10-21 2022-05-19 Novartis Ag TIM-3 inhibitors and uses thereof
US20230000864A1 (en) 2019-11-22 2023-01-05 Sumitomo Pharma Oncology, Inc. Solid dose pharmaceutical composition
CA3165399A1 (en) 2019-12-20 2021-06-24 Novartis Ag Uses of anti-tgf-beta antibodies and checkpoint inhibitors for the treatment of proliferative diseases
US20230058489A1 (en) 2020-01-17 2023-02-23 Novartis Ag Combination comprising a tim-3 inhibitor and a hypomethylating agent for use in treating myelodysplastic syndrome or chronic myelomonocytic leukemia
JP2023516155A (ja) 2020-02-28 2023-04-18 ノバルティス アーゲー ダブラフェニブ、ｅｒｋ阻害剤及びｒａｆ阻害剤又はｐｄ－１阻害剤を含む三重の医薬品の組合せ
IL296226A (en) 2020-04-21 2022-11-01 Novartis Ag Dosing regimen for the treatment of CSF-1r regulated disease
WO2022009157A1 (en) 2020-07-10 2022-01-13 Novartis Ag Lhc165 and spartalizumab combinations for treating solid tumors
US20230338587A1 (en) 2020-08-31 2023-10-26 Advanced Accelerator Applications International Sa Method of treating psma-expressing cancers
WO2022043557A1 (en) 2020-08-31 2022-03-03 Advanced Accelerator Applications International Sa Method of treating psma-expressing cancers
IL302569A (en) 2020-11-06 2023-07-01 Novartis Ag CD19 binding molecules and their uses
TW202237119A (zh) 2020-12-10 2022-10-01 美商住友製藥腫瘤公司 Ａｌｋ﹘５抑制劑和彼之用途
AR124414A1 (es) 2020-12-18 2023-03-22 Century Therapeutics Inc Sistema de receptor de antígeno quimérico con especificidad de receptor adaptable
TW202241508A (zh) 2021-01-29 2022-11-01 美商艾歐凡斯生物治療公司 細胞介素相關之腫瘤浸潤性淋巴球組合物及方法
EP4284510A1 (en) 2021-01-29 2023-12-06 Novartis AG Dosage regimes for anti-cd73 and anti-entpd2 antibodies and uses thereof
TW202304979A (zh) 2021-04-07 2023-02-01 瑞士商諾華公司 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
PE20240327A1 (es) 2021-04-13 2024-02-22 Nuvalent Inc Heterociclos con sustitucion amino para tratar canceres con mutaciones de egfr
WO2023147488A1 (en) 2022-01-28 2023-08-03 Iovance Biotherapeutics, Inc. Cytokine associated tumor infiltrating lymphocytes compositions and methods

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5001225A (en) * 1986-12-08 1991-03-19 Georgetown University Monoclonal antibodies to a pan-malarial antigen
US5576184A (en) * 1988-09-06 1996-11-19 Xoma Corporation Production of chimeric mouse-human antibodies with specificity to human tumor antigens
US5571894A (en) * 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
IL108501A (en) * 1994-01-31 1998-10-30 Mor Research Applic Ltd Antibodies and pharmaceutical compositions containing them
US5897882A (en) * 1996-04-12 1999-04-27 Gonzalez; Juan Glass repair system
TW517067B (en) * 1996-05-31 2003-01-11 Hoffmann La Roche Interferon conjugates
JP3886238B2 (ja) * 1997-02-12 2007-02-28 中外製薬株式会社 リンパ球系腫瘍の治療剤
JPH1142087A (ja) * 1997-07-29 1999-02-16 Sumitomo Electric Ind Ltd 抗ヒトプレｂ細胞レセプター抗体およびその活性フラグメントならびにヒトプロｂ細胞の検出方法
US7442776B2 (en) * 1999-10-08 2008-10-28 Young David S F Cancerous disease modifying antibodies
IL149820A0 (en) 2002-05-23 2002-11-10 Curetech Ltd Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency
US7393531B2 (en) * 2003-01-21 2008-07-01 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of MCSP

Also Published As

Publication number Publication date
AU776464C (en) 2005-05-12
WO2000058363A1 (en) 2000-10-05
US7695715B2 (en) 2010-04-13
CN1267452C (zh) 2006-08-02
KR20020008140A (ko) 2002-01-29
US20030026800A1 (en) 2003-02-06
JP2003500015A (ja) 2003-01-07
ZA200106809B (en) 2002-08-19
CA2367901C (en) 2013-03-19
EP1165616A1 (en) 2002-01-02
IL145535A0 (en) 2002-06-30
RU2235131C2 (ru) 2004-08-27
DE69922261T2 (de) 2005-12-01
AU5996599A (en) 2000-10-16
NZ513498A (en) 2004-01-30
CN1346371A (zh) 2002-04-24
EP1165616B1 (en) 2004-11-24
BR9917218A (pt) 2001-12-26
AU776464B2 (en) 2004-09-09
HUP0200537A2 (en) 2002-06-29
IL145535A (en) 2008-06-05
CA2367901A1 (en) 2000-10-05
DE69922261D1 (de) 2004-12-30
ATE283289T1 (de) 2004-12-15
US20060099209A1 (en) 2006-05-11

Similar Documents

Publication Publication Date Title
IL129299A0 (en) Monoclonal antibodies antigens and diagnosis of malignant diseases
UA90082C2 (ru) Выделенное моноклональное антитело человека, которое специфически связывается с cd25 человека и ингибирует связывание il-2 с cd25
DK1759013T3 (da) Identificering af overflade-associerede antigener til tumordiagnose
MA30962B1 (fr) Anticorps antifacteurs d'humanisés et leurs utilisations.
WO2001030854A3 (en) Antibody to human gastrointestinal epithelial tumor antigen related to alpha 6 beta 4 integrin
EP2292644A3 (en) Small Streptococcus pyogenes antigens and their use
CA2000913A1 (en) Family of high affinity antibodies for cancer treatment
WO2004003155A3 (en) Humanized anti-tag-72 cc49 for diagnosis and therapy of human tumors
EP2192407A3 (en) Method of detecting cellular immunity and application thereof to drugs
CN113667011B (zh) 制备抗原结合单元的方法
SG156619A1 (en) Novel cancer associated antibodies and antigens and their use in cancer diagnosis
AU2001270518A1 (en) Hypha-specific factors from candida albicans
WO1998004585A3 (en) Novel human macrophage antigen
WO2006089422A8 (en) Protein and its use in diagnosing alzheimer's disease
UA93478C2 (ru) Выделенное моноклональное антитело человека, kotopoe связывается c cd20, и его применение
MD2513G2 (ro) Metodă de diagnostic precoce al infarctului miocardic acut